v3.26.1
Note 2 - Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2025
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
  

For the Year Ended

 
  

December 31,

 
  

2025

  

2024

 

Revenues

 $819  $420 

Less:

        

Cost of revenues

  63   42 

Acquired in-process research and development expense

  1,967    

Loss on impairment of intangible assets

  6,995    

Loss on debt extinguishment

  3,260    

Depreciation and amortization expense

  2,115   2,109 

Stock-based compensation expense

  338   54 

Salaries and benefits expense

  4,471   4,192 

Professional fees

  2,167   2,034 

Research and development expense

  862   272 

Interest income

  (34)  (81)

Interest expense

  281   91 

Change in fair value of royalties payable due to related parties

  (5,709)  2,239 

Change in fair value of convertible notes payable

  (2)   

Net loss on trading debt securities

  564    

Income tax provision (benefit)

  (1,810)  3,141 

Other segment items (1)

  2,986   2,970 

Segment net loss

  (17,695)  (16,643)
         

Reconciliation of net loss

        

Adjustments and reconciling items

      

Consolidated net loss

 $(17,695) $(16,643)
Fair Value, by Balance Sheet Grouping [Table Text Block]
      

December 31, 2025

     
  

Total

  

Level 1

  

Level 2

  

Level 3

 

Assets:

                

Cash Equivalents

                

Money market funds

 $2  $2  $  $ 

Total assets

 $2  $2  $  $ 
                 

Liabilities:

                

Royalties payable due to related parties

 $792  $  $  $792 

Convertible notes payable

  298         298 

Total liabilities

 $1,090  $  $  $1,090 
      

December 31, 2024

     
  

Total

  

Level 1

  

Level 2

  

Level 3

 

Assets:

                

Cash Equivalents

                

Mutual funds

 $2,803  $2,803  $  $ 

Money market funds

  12   12       

Total assets

 $2,815  $2,815  $  $ 
                 

Liabilities:

                

Current portion of royalties payable due to related parties

 $145  $  $  $145 

Royalties payable due to related parties

  9,068         9,068 

Total liabilities

 $9,213  $  $  $9,213 
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
  

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

 
  

Royalties Payable due to Related Parties

  

Convertible Notes Payable

 

Balance at January 1, 2025

 $9,213  $ 

Issuance of convertible notes payable

     300 

Exchange of royalties payable due to related parties (see Note 8)

  (2,712)   

Change in fair value

  (5,709)  (2)

Balance at December 31, 2025

 $792  $298 
  

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

 
  

Royalties Payable due to Related Parties

  Convertible Notes Payable 

Balance at January 1, 2024

 $6,974  $ 

Change in fair value

  2,239    

Balance at December 31, 2024

 $9,213  $ 
Fair Value Measurements, Nonrecurring [Table Text Block]
      

December 31, 2025

     
  

Total

  

Level 1

  

Level 2

  

Level 3

 

Assets:

                

VIVO Intangible Assets

 $184  $  $  $184 
Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]

Machinery and equipment

  2 - 5 years 

Computer hardware and software

  1 - 5 years 

LockeT animation video

  3 years 

VIVO DEMO/Clinical Systems

  1-5 years 
Disaggregation of Revenue [Table Text Block]
  

For the Year Ended December 31,

  

2025

  

2024

Product sales

       

US

 $655  $278

Europe

  164   142

Total product sales

 $819  $420
Royalties Payable [Member]  
Notes Tables  
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

December 31, 2025

 

Instrument

Valuation Technique

Unobservable Input

 

Input Range

 

Royalties payable due to related parties

Discounted future cash flows

Revenue adjusted discount rate

  19.5%

December 31, 2024

 

Instrument

Valuation Technique

Unobservable Input

 

Input Range

 

Royalties payable due to related parties, including the current portion

Discounted future cash flows

Revenue adjusted discount rate

  22.5%

December 31, 2025

 

Instrument

Valuation Technique

Unobservable Input

 

Input Range

 

Intangible assets - Developed technology

Multi-period excess earnings

Discount rate

  22%
  

Annual obsolescence rate (pre-patent expiration)

  95.0%
  

Annual obsolescence rate (post-patent expiration)

  75.0%

Intangible assets - Trade Name

Relief from royalty

Discount rate

  22%
  

Pre-tax royalty rate

  1.0%